MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Biodesix Interest Expense 2011-2026 | BDSX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Biodesix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.26 M | 9.54 M | 8.07 M | 4.51 M | 7.6 M | 3.01 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.54 M | 3.01 M | 6.83 M |
Quarterly Interest Expense Biodesix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.07 M | 1.9 M | 1.68 M | - | 2.04 M | 1.94 M | 2.53 M | - | 2 K | 2.43 M | 2.39 M | - | 3.04 M | 1.35 M | 1.14 M | - | 1.55 M | 815 K | 651 K | - | 2.66 M | 2.78 M | 1.46 M | - | 706 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.04 M | 2 K | 1.74 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.87 | -3.04 % | $ 93.1 K |  USA |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
81 M | $ 118.59 | 0.39 % | $ 36.1 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 108.89 | 0.54 % | $ 4.3 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
1 K | $ 27.69 | -1.07 % | $ 769 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 175.98 | -1.49 % | $ 8.72 B | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 13.9 | -2.11 % | $ 420 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.11 | -2.63 % | $ 1.41 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 209.65 | -0.29 % | $ 23.3 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 203.85 | -0.99 % | $ 145 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.36 | 0.01 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
1.29 M | $ 8.85 | 0.91 % | $ 554 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 10.3 | -4.19 % | $ 292 M |  Israel |
 |
DexCom
DXCM
|
177 M | $ 73.26 | -0.7 % | $ 28.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 24.01 | -4.59 % | $ 254 M | China |
 |
VolitionRx Limited
VNRX
|
-233 K | $ 0.2 | -2.17 % | $ 19.2 M |  Singapore |
 |
CareDx, Inc
CDNA
|
524 K | $ 18.74 | -0.03 % | $ 999 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 108.07 | -0.18 % | $ 8.91 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 639.3 | 0.41 % | $ 51.4 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 130.84 | -1.54 % | $ 20.8 B | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Guardant Health
GH
|
-10.5 M | $ 94.83 | 2.82 % | $ 11.9 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 283.93 | -0.81 % | $ 23.6 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 79.25 | 3.87 % | $ 5.35 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 174.04 | -0.14 % | $ 29.9 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | - | - | $ 79.8 M | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 317.21 | -0.44 % | $ 27.1 B |  Schweiz |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 5.32 | 6.19 % | $ 493 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 9.71 | 2.21 % | $ 1.24 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
9.32 M | $ 209.59 | 4.71 % | $ 20.6 B | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.55 | -4.63 % | $ 465 M | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 11.01 | -1.26 % | $ 2.39 B | USA |
 |
Precipio
PRPO
|
-1 K | $ 24.7 | 0.08 % | $ 32.1 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |